Company Showcase

Image
NINDS SBIR graphic

 

The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.

Here we present nonconfidential company information about a subset of awardees ready to attract third-party collaborators and investors.


Image
4E Therapeutics logo

4E Therapeutics, delivering innovative medicines for pain 


Image
Aquilis Pharmaceuticals logo

Aquilus Pharmaceuticals is a biotech company focused on the treatment and management of amyotrophic lateral sclerosis (ALS), neuropathic pain and other neurological disorders. 


 

Image
Dignify Therapeutics Logo

Dignify Therapeutics, restoring voluntary control of bowel and bladder for people with neurological disorders, diabetes, and the elderly.


Image
Eysz logo

Eysz is building an AI-based software platform that uses eye-movement data as input to identify patterns associated with consciousness, cognition, and mood to help doctors and pharma companies measure disease progression and treatment outcomes for neurological disorders starting with epilepsy. 


Image
ImmunoChem Therapeutics logo

Great Lakes NeuroTechnologies, the leader in remote monitoring of movement disorders, markets KinesiaU™, enabling doctors to provide personalized, efficient, accurate therapy titration with fewer office visits, saving time and money.


Image
ImmunoChem Therapeutics logo

ImmunoChem Therapeutics, LLC, blocking neuroinflammation to stop cognitive decline.


 

Image
Neurexis Therapeutics logo

Neurexis Therapeutics, neuroprotective peptides for cerebral ischemia.


Image
NuvOx_Therapeutics_logo

NuvOx Pharma, Mobilizing Oxygen, Transforming Lives.


Image
Palm Therapeutics logo

Palm Therapeutics is leveraging a proprietary drug discovery platform to develop first-in-class cancer therapies.


Image
PathMakers Neurosciences Inc. logo

 

 

 

 

 

PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders including stroke and ALS. 


Image
Plumeria Therapeutics logo

Plumeria Therapeutics, Inc. is a pain therapeutic company developing a novel, non-opioid drug guided by a companion diagnostic. 

 


Image
Rebion Neural Performance Scanning logo

Rebion is commercializing a breakthrough diagnostic platform technology to definitively identify life-altering conditions that manifest from functional impairments in the brain, including lazy eye and traumatic brain injury.

  


Image
Sinopia Biosciences logo

Sinopia Biosciences is an AI/machine learning drug discovery company advancing novel therapeutics in neurology, oncology, and rare diseases, with a first-in-class small molecule for Parkinson’s disease.

 


Image
Sinopia logo

SNJ Pharma’s SNJ101, the first plasmin-independent thrombolytic agent, aims to revolutionize the treatment of ischemic diseases by addressing the bleeding complications associated with current thrombolytic therapies, providing a therapeutic option for over 200 million patients. 


Image
South Rampart Pharma logo

South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines.